TORONTO, June 19, 2017 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (“WeedMD” or the “Corporate”), a federally authorized manufacturer of clinical hashish, is happy to announce that on June 16, 2017, the Corporate won a supplemental license from Well being Canada for the manufacturing of clinical hashish oils.
The Corporate has imported a purpose-built high-throughput ethanol extraction system from Germany, with the function of beginning R&D and manufacturing of hashish oils straight away. After thorough research, WeedMD concluded that ethanol extraction is able to generating a blank product that meets and exceeds the regulator’s strict pointers, whilst offering a scalable and low cost platform to carrier the longer term call for for oil and different extracted merchandise. As soon as the Corporate has produced and inventoried saleable batches of oil, it is going to invite Well being Canada to behavior a last inspection to protected an modification allowing the sale of hashish oils.
“That is the most important milestone in our trail and dedication to offering physicians and their sufferers with choice, extra handy and dose-controlled intake strategies,” mentioned Bruce Dawson-Scully, CEO of WeedMD. “We look ahead to offering our sufferers with constant, high quality product in quite a few intake strategies in addition to teaching them and the clinical neighborhood on the advantages of oil extracts. In line with information launched through Well being Canada, hashish oil gross sales keep growing at a quicker fee than dried flower, and WeedMD will now be located to serve the long run care and seniors marketplace with hashish oil.”
For more info, get admission to our investor presentation on our website online right here.
About WeedMD Inc.
WeedMD Inc. is an authorized manufacturer of clinical hashish pursuant to the Get entry to to Hashish for Clinical Functions Rules (ACMPR). WeedMD operates a 26,000 sq. foot, scalable manufacturing facility in Aylmer, Ontario with 4 acres of assets for long run growth. WeedMD is keen on offering constant, high quality drugs to the long-term care and assisted residing markets in Canada via its complete platform advanced solely for that trade. WeedMD is devoted to teaching healthcare practitioners and furthering public figuring out of the function clinical hashish can play as a viable choice to prescription medicine in relieving quite a few power clinical prerequisites and diseases.
Practice WeedMD On:
To be informed extra, consult with us at www.weedmd.com
Ahead-Taking a look Knowledge
This press free up accommodates forward-looking data in keeping with present expectancies. Statements in regards to the date of buying and selling of the Corporate’s commonplace stocks at the Alternate and ultimate regulatory approvals, amongst others, are forward-looking data. Those statements will have to now not be learn as promises of long run efficiency or effects. Such statements contain recognized and unknown dangers, uncertainties and different elements that can reason exact effects, efficiency or achievements to be materially other from the ones implied through such statements. The Corporate assumes no accountability to replace or revise forward-looking data to mirror new occasions or instances except required through regulation.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
For additional data, please touch: WeedMD Inc. Keith Merker, Leader Monetary Officer Tel: 519-765-2440 Ext. 222 E mail: email@example.com